Congenital Hyperinsulinism
Information
- Disease name
- Congenital Hyperinsulinism
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03941236 | Active, not recruiting | Phase 3 | Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism | May 1, 2019 | January 1, 2025 |
| NCT00674440 | Completed | Phase 2 | Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism | December 2004 | January 2009 |
| NCT00897676 | Completed | Phase 1/Phase 2 | Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity | May 2009 | January 2017 |
| NCT00987168 | Completed | Phase 2 | Sandostatine® LP and Hyperinsulinism | May 2009 | June 2011 |
| NCT01070758 | Completed | Phase 4 | Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy | February 2010 | February 2015 |
| NCT00571324 | Completed | Phase 1/Phase 2 | Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism | August 2007 | December 2014 |
| NCT02604485 | Completed | Phase 2 | A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism | October 2015 | January 2017 |
| NCT02937558 | Completed | Phase 2 | CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism | October 2016 | October 2018 |
| NCT03042416 | Completed | Phase 3 | 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety | June 29, 2017 | June 2, 2021 |
| NCT03777176 | Completed | Phase 3 | A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism | February 7, 2019 | October 5, 2020 |
| NCT04172441 | Completed | Phase 2/Phase 3 | Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism | June 22, 2020 | March 7, 2022 |
| NCT04538989 | Completed | Phase 2 | An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism | February 24, 2020 | August 19, 2022 |
| NCT02533219 | No longer available | Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia | |||
| NCT02835131 | No longer available | Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia | |||
| NCT02021604 | Recruiting | Phase 1 | Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma | October 9, 2013 | June 2028 |
| NCT06208215 | Recruiting | Phase 3 | RZ358 Treatment for Congenital Hyperinsulinism | January 11, 2024 | September 28, 2026 |
| NCT04706910 | Recruiting | Phase 3 | 18F-DOPA II - PET Imaging Optimization | January 20, 2021 | July 2026 |
| NCT04732416 | Recruiting | Phase 2 | HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) | October 28, 2021 | March 31, 2025 |
| NCT04205604 | Recruiting | Phase 2 | 18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism | November 3, 2016 | December 31, 2026 |
| NCT00835328 | Terminated | Phase 1/Phase 2 | Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia | August 26, 2009 | January 28, 2017 |
| NCT03768518 | Unknown status | GLP-1 Receptor Expression in CHI | February 7, 2018 | February 1, 2019 | |
| NCT03053284 | Withdrawn | Phase 2 | Pasireotide in Hyperinsulinemic Hypoglycemia | April 2017 | April 2018 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D044903